|
|
|
|
Romania's unwanted children given a chanceIn December 1989, the collapse of Romanian dictator Nicolae Ceausescu's regime revealed the plight of thousands of malnourished orphans locked away in filthy, unheated institutions. ...Source: RSS feed - channel BNewsHealth | 13 Dec 2009 | 12:45 am 21st-Century Babies: Uncertain Laws on Surrogates Leave Custody at IssueSurrogacy is largely without regulation, creating an emerging commercial market for babies that raises vexing ethical questions. Source: NYT > Health | 13 Dec 2009 | 12:10 am S.Africa tackles World Cup child trafficking fearsLesotho-born Thato was brought to South Africa at age three, by a woman she knew simply as "granny". Five years later, her "granny" sold her into sexual slavery. The woman who bought herSource: RSS feed - channel BNewsHealth | 12 Dec 2009 | 11:18 pm Poor being turned away from free cancer screenings (AP)
Source: Yahoo! News: Health News | 12 Dec 2009 | 9:51 pm Sam's story'He was only five with multiple sclerosis'Source: BBC News | Health | World Edition | 12 Dec 2009 | 6:00 pm Menopause, as Brought to You by Big PharmaLawsuits and internal documents show how Pfizer and its predecessors promoted the idea of taking hormone drugs.Source: NYT > Health | 12 Dec 2009 | 3:38 pm Poor being turned away from free cancer screeningsLow-income women nationwide are being turned away or put on long waiting lists for free cancer screenings. The American Cancer Society's Cancer Action Network says the economy has forcedSource: RSS feed - channel BNewsHealth | 12 Dec 2009 | 11:52 am Protesters condemn Swiss minaret banSome 500 protesters gathered outside parliament in Bern on Saturday to condemn a Swiss ban on the building of new minarets, approved in a referendum last month. Some were seen with...Source: RSS feed - channel BNewsHealth | 12 Dec 2009 | 11:19 am Slipstream: Sure, It’s Treatable. But Is It a Disorder?Two pharmaceutical companies have developed drugs to fight premature ejaculation, and hope they will become blockbusters like drugs for erectile dysfunction.Source: NYT > Health | 12 Dec 2009 | 11:13 am Poor Children Likelier to Get AntipsychoticsSome children from poor families may be receiving powerful drugs because it is deemed a cheaper way to treat a problem.Source: NYT > Health | 12 Dec 2009 | 9:23 am Count down for Miss World title beginsBeauty queens from around the globe vying for the Miss World title prepare Saturday for a night of glitz, glamour and suspense, while claims of religious cult links swirl around one...Source: RSS feed - channel BNewsHealth | 12 Dec 2009 | 5:43 am EADS eyes takeovers to double sales by 2020 -reportFRANKFURT, Dec 12 (Reuters) - European aerospace group EADS wants to use takeovers -- primarily in the services sector -- to help group revenue swell over the next decade, its chief executive told a German...Source: RSS feed - channel BNewsHealth | 12 Dec 2009 | 3:26 am BiPar Sciences Announces Update On The Clinical Development Progress Of BSI-201 For Metastatic Triple-Negative Breast CancerSanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly-owned subsidiary, BiPar Sciences, announced that the clinical development program in metastatic triple-negative breast cancer (mTNBC) for the investigational PARP1 inhibitor, BSI-201, progresses as planned with the Phase 3 study meeting expectations on patient accrual and trial site coverage in the United States. Study investigators have enrolled 214 of the target number of 420 patients...
Source: Health News from Medical News Today | 12 Dec 2009 | 3:00 am Roche, Genentech And Biogen Idec Announce Positive Results From First Phase III Trial Of Ocrelizumab In Rheumatoid ArthritisRoche (SIX: RO, ROG; OTCQX: RHHBY), Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) announced a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks...
Source: Health News from Medical News Today | 12 Dec 2009 | 3:00 am Novartis Tasigna® Trial Shows Superior Results To Glivec® In Patients With Early-stage Chronic Myeloid LeukemiaIn a large Phase III clinical trial, Tasigna® (nilotinib) demonstrated greater efficacy over Glivec® (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase[1]...
Source: Health News from Medical News Today | 12 Dec 2009 | 3:00 am Novartis Receives Approval In The European Union For Onbrez® Breezhaler®, A New Once-daily Bronchodilator For Patients With COPDNovartis announced that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). "Onbrez Breezhaler has demonstrated greater improvements in lung function, breathlessness and quality of life compared to current therapies," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division...
Source: Health News from Medical News Today | 12 Dec 2009 | 3:00 am Merck KGaA Starts Stimuvax Phase III Study INSPIRE In Asian Patients With Advanced NSCLCMerck KGaA announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The INSPIRE(a) study will investigate if Stimuvax can extend overall survival in Asian patients with unresectable stage III NSCLC. INSPIRE is being initiated in five Asian regions...
Source: Health News from Medical News Today | 12 Dec 2009 | 3:00 am Algeta Announces First US Patient Randomized In ALSYMPCA Phase III Study At Tulane Cancer Center, New OrleansAlgeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton...
Source: Health News from Medical News Today | 12 Dec 2009 | 2:00 am NICE Guidelines Ration Affordable Osteoporosis DrugsLow cost osteoporosis drugs are strictly rationed for the under 75s, and UK physicians hampered by restrictive guidelines, according to findings which appear in the journal Therapeutic Advances in Musculoskeletal Disease, published by SAGE. A leading Cambridge University bone health expert has outlined flaws in NICE osteoporosis treatment guidance, which limits options for many postmenopausal women in the under-75 age bracket. According to Cambridge University Professor of Bone Medicine, Juliet Compston, the current UK guidelines are unnecessarily complex...
Source: Health News from Medical News Today | 12 Dec 2009 | 2:00 am Clinical Programs With Riociguat In Pulmonary Hypertension Well On TrackA first Phase II trial with Bayer Schering Pharma's oral agent riociguat (BAY 63-2521) in pulmonary hypertension owing to interstitial lung disease (PH-ILD) has successfully been completed. PH-ILD is a form of pulmonary hypertension for which no approved treatment options are currently available. The primary objectives of the study to investigate safety and tolerability of riociguat in this subgroup of PH-patients were achieved...
Source: Health News from Medical News Today | 12 Dec 2009 | 2:00 am Italy's Poor Go To Hospital MoreDespite free public healthcare, Italy's poor are more likely to end up in hospital with avoidable conditions, new research shows. This pattern, reported today in the online open access journal BMC Public Health, mirrors findings from a number of different healthcare systems around the world, although to date fewer studies have been completed in Europe. A research team led by Nera Agabiti at the Department of Epidemiology, ASL RM/E Rome (Italy) used hospital discharge data from the year 2000 from Rome, Bologna, Turin and Milan...
Source: Health News from Medical News Today | 12 Dec 2009 | 2:00 am Novel Detection Method Unmasks Circulating Breast Cancer CellsCirculating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center. The findings were presented at the CTRC-AACR San Antonio Breast Cancer Symposium. Levels of these circulating tumor cells (CTCs) - which are shed from a primary tumor or its metastases - have been used to monitor and tailor cancer therapy and to predict a patient's prognosis...
Source: Health News from Medical News Today | 12 Dec 2009 | 2:00 am
|
